What Happened?
Shares of dialysis provider DaVita Inc. (NYSE: DVA) fell 7.1% in the afternoon session after Axios reported that the Department of Health and Human Services released a new kidney care plan from the Trump administration.
According to the report, the initiative calls for introducing more competition into treatment markets and incentivizing innovation across the sector. The federal plan also places a greater emphasis on preventive care to treat chronic kidney disease before it reaches late stages. The policy aims to support new treatment approaches and encourage competition while prioritizing early intervention for patients with kidney conditions.
The shares closed the day at $175.08, down 6.4% from the previous close.
The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Is now the time to buy DaVita? Access our full analysis report here, it’s free.
What Is The Market Telling Us
DaVita’s shares are not very volatile and have only had 9 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful, although it might not be something that would fundamentally change its perception of the business.
The biggest move we wrote about over the last year was 9 months ago when the stock gained 25.3% on the news that the company reported fourth-quarter results that topped Wall Street's expectations and issued a robust earnings forecast for 2026.
The company's total revenue for the quarter reached $3.62 billion, a 9.9% year-over-year increase that beat the consensus estimate of $3.51 billion. DaVita also reported an adjusted profit of $3.40 per share, which was 6.5% above analysts' projections.
Looking ahead, the company provided a strong outlook, guiding for 2026 adjusted earnings per share with a midpoint of $14.30. This forecast significantly exceeded Wall Street's prior expectations, signaling strong confidence in future profitability and driving positive investor sentiment.
DaVita is up 51.7% since the beginning of the year, but at $173.72 per share, it is still trading 27.9% below its 52-week high of $240.96 from July 2026. Investors who bought $1,000 worth of DaVita’s shares 5 years ago would now be looking at an investment worth $1,522.
WHILE YOU’RE HERE: The Next Palantir? One satellite company captures images of every point on Earth. Every single day. The Pentagon wants it. Hedge funds are using it to beat earnings. You’ve probably never heard of it.
This is what the early days of Palantir looked like before it became a giant. Same playbook. Different technology. If you missed Palantir, you need to see this. Claim The Stock Ticker for Free HERE.
